| Compound | Hexarelin |
|---|---|
| Category | GH-releasing hexapeptide |
| Class | Growth Hormone and Growth Factors |
| Evidence tier | Preclinical |
| WADA status | Prohibited in sport (or falls under a prohibited class) — see the WADA reference table |
| Sold on this site | No — this is a reference database |
Overview
Hexarelin is catalogued here as a gh-releasing hexapeptide and graded at the "Preclinical" evidence tier. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A potent GHRP-family hexapeptide studied for GH stimulation in early clinical research, including cardiac contexts, but never developed into an approved medicine.
Mechanism of Action
Hexarelin is a strong ghrelin-receptor agonist producing larger GH pulses than many siblings, with some evidence of direct cardiac receptor effects independent of GH release.
Research and Evidence
Small human studies characterized GH response and cardiac hemodynamics in the 1990s–2000s; development for heart failure indications did not reach approval.
Safety and Side Effects
Prolactin and cortisol responses were observed at higher doses. It is prohibited in sport.
Frequently Asked Questions
What is the evidence tier of Hexarelin?
Hexarelin is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is Hexarelin an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Hexarelin?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.